



Fred Hutch
Cancer Center

16th Annual Hematology and Oncology Review Course

(On-Demand)

December 1, 2025 – November 30, 2026

Enduring Material

UW Medicine

Course Syllabus

Table of Contents

	Page
Course Information	3
CME Accreditation	3
Access Instructions	4
Faculty Disclosure Summary	5-7
Credit Tracking Sheet	8
Notes Pages	9-20



Scan the QR code

Subscribe to our e-newsletter to learn about future education opportunities from Fred Hutchinson Cancer Center.

fredhutch.org/provider-blog

Course Information

COURSE DESCRIPTION

Join our renowned experts from Fred Hutchinson Cancer Center and the University of Washington School of Medicine for the 16th Annual Comprehensive Hematology and Oncology Review Course. This program includes 54 talks covering medical oncology and hematology standard-of-care updates, as well as talks reviewing integrative medicine, infectious disease complications, a multi-disease talk on radiation oncology, and benign white cell disorders. The lectures review data that inform current guidelines, recommendations, and recent advances regarding therapeutic options for patients with solid tumors and malignant and benign hematologic disorders. After completing the course, learners will have a deeper understanding of the pathogenesis, diagnostic evaluation, and therapeutic modalities available for a breadth of solid tumors and hematologic disorders.

COURSE OBJECTIVES

Upon completion of this activity, attendees should be able to:

- Describe the pathogenesis, diagnostic evaluation, and therapeutic modalities available for common malignant hematological diseases.
- Explain the pathogenesis, diagnostic evaluation, and therapeutic modalities available for common solid tumor malignancies.
- Integrate guideline-based treatments into clinical practice while personalizing care appropriately for the patient.
- Organize new therapeutic and diagnostic approaches into clinical practice as appropriate.

TARGET AUDIENCE

This educational program is intended for physicians, advanced practice providers, nurses, pharmacists, residents and fellows interested in a comprehensive update on solid tumors and hematologic disorders, and will be of interest to those certifying or re-certifying for their boards.

ACCREDITATION (December 1, 2025 – November 30, 2026)

Accreditation with Commendation

The University of Washington School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

The University of Washington School of Medicine designates this enduring material for a maximum of 34.5 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME CREDIT AND CERTIFICATES

In order to receive Continuing Medical Education credit (*AMA PRA Category 1 Credits*[™]) or a Certificate of Attendance, completion of the electronic evaluation and attendance attestation is required and is located under the first module. This process must be completed prior to the end of the accreditation term (November 30, 2026). Certificates can then be accessed by going to myCME→ Evaluations & Certificates.

Syllabus Access

Registration to this course grants online access to the conference syllabus materials from the UW CME website. Please visit www.uwcme.org. Click on “Sign In” and log in using the email you registered with for the program and password.



Click on the following URL: <https://uw.cloud-cme.com/EN2602>

EN2602: Comprehensive Hematology and Oncology Review Course

Overview

Tests

- To access the content, elect “Tests.” All PDF and video content is available, grouped by modules. You can watch them as often as you would like through November 30, 2026.
- To view the PDF of the presentations, please click the provided link. After viewing, you can return to the main course page by clicking the back arrow in your browser or by using the course URL.
- Please do not complete the CME Attestation and Evaluation selection until you are sure you are done watching content for credit.

METHOD OF PARTICIPATION

Access to the internet is required. Each talk will have its associated presentation, recording and supplemental questions located in the Q&A document. Please make sure to review all three as part of the learning process. Completion of the credit attestation and evaluation are required in order to receive CME credit. This should be done at the conclusion of your learning and should be tracked using the included tracking sheet.

COPYRIGHT

The content is the property of the University of Washington and Fred Hutch Cancer Research Center and is protected by law, including but not limited to copyright and trademark statutes. This content is for educational purposes only and may not be used for commercial gain. The University of Washington and Fred Hutch Cancer Research Center reserve the right to revise or withdraw content from use. Redistribution of this content is strictly prohibited. For questions related to content use, please contact the CME office at cme@uw.edu.

Technical Assistance: If you need assistance accessing your account, or navigating the online system, please contact UW CME at cme@uw.edu.

INTERNET BROWSER

The CloudCME system works best with Chrome or Firefox.

DISCLOSURE INFORMATION

The University of Washington School of Medicine requires any person in control of content disclose any financial relationships with ineligible companies. Disclosure of a relationship is not intended to suggest or condone bias in any presentation, but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. The ACCME defines an ineligible company as a company “*whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.*”

The University of Washington School of Medicine is required to “mitigate” any conflicts prior to the educational program. Therefore, in light of the relationships/affiliations designated, each person in control of content has attested that:

- recommendations for patient care are based on current science, evidence, and clinical reasoning, while giving a fair and balanced view of diagnostic and therapeutic options;
- all scientific research referred to, reported, or used in this educational activity in support or justification of a patient care recommendation conform to the generally accepted standards of experimental design, data collection, analysis, and interpretation;
- new and evolving topics for which there is a lower (or absent) evidence base are clearly identified as such;
- content avoids advocating for, or promoting, practices that are not, or not yet, adequately based on current science, evidence, and clinical reasoning;
- content excludes any advocacy for, or promotion of, unscientific approaches to diagnosis or therapy, or recommendations, treatment, or manners of practicing healthcare that are determined to have risks or dangers that outweigh the benefits or are known to be ineffective in the treatment of patients.

All relevant financial relationships have been mitigated.

Faculty

Description of Relationship

Christina Baik, MD	Grant or research support -Daiichi Sankyo, Inc., Nuvalent, AbbVie, Bristol-Myers Squibb Comp (BMS), AstraZeneca, Lilly, Pfizer, Janssen, Boehringer Ingelheim Pharmaceuticals, Inc.
Kalyan Banda, MD	Grant or research support -Lilly, Regeneron Pharmaceuticals, Inc., MorphoSys, Gilead Sciences, Inc
Rahul Banerjee, MD	Consulting Fee -Adaptive Biotechnologies, Bristol-Myers Squibb Comp (BMS), Caribou Biosciences, GlaxoSmithKline (GSK), Janssen, Karyopharm Therapeutics, Legend Biotech, Pfizer, Sanofi S.A., SparkCures, AbbVie, Gilead Sciences, Inc., Genentech; Grant or research support -AbbVie, Bristol-Myers Squibb Comp (BMS), Janssen, Novartis Corporation Pharmaceuticals, Prothena, Sanofi S.A, Pack Health
Shailender Bhatia, MD	Advisor -Bristol-Myers Squibb Comp (BMS), Replimune; Grant or research support -Incyte Corporation, EMD Serono; Travel support for abstract presentation -Regeneron Pharmaceuticals, Inc.
Ryan Cassaday, MD (Faculty, planner, reviewer)	Grant or research support -Amgen, Inc., Incyte Corporation, Servier; Membership on Advisory Committees or Review Panels, Board Membership, etc. -Autolus, PeproMene Bio
Andrew Coveler, MD	Grant or research support -AstraZeneca, Pfizer, Nucana, Amgen, Inc., Kyowa Kiran, Daiichi Sankyo, Inc., PMV Pharma, BeiGene

Mengyang Di, MD	Grant or research support -Dren Bio, AbbVie, Lilly, Regeneron Pharmaceuticals, Inc., BeiGene, Schrodinger; Consulting Fee -Genentech
Keith Eaton, MD	Grant or research support -Mirati Therapeutics
David Garcia, MD	Independent Contractor (included contracted research) -Abbott
Solomon Graf, MD	Grant or research support -Janssen, Lilly, BeiGene, Genentech, AstraZeneca
William Gwin, MD	Advisor -AstraZeneca, Gilead Sciences, Inc.; Grant or research support -Amazon
Anna Halpern, MD	Grant or research support -Merck, PharmEssentia, Protagonist, Disc Medicine, Karyopharm Therapeutics, Jazz Pharmaceuticals, Inc., Incyte Corporation, Sumitomo, Chordia, ; Consulting Fee -Karyopharm Therapeutics, BMS
William Harris, MD	Advisor -Boston Scientific Corporation; Grant or research support -AstraZeneca, Eureka Therapeutics, Rayzebio; Consulting Fee -ICON, WCG
Sara Hurvitz, MD	Grant or research support -Arvinas, AstraZeneca, Daiichi Sankyo, Inc., Celcuity, Genentech, Roche, Gilead Sciences, Inc., Lilly, Novartis Corporation Pharmaceuticals, Orum, Pfizer, Seagen, Jazz Pharmaceuticals, Inc.; Membership on Advisory Committees or Review Panels, Board Membership, etc. -Boehringer Ingelheim Pharmaceuticals, Inc., BeiGene, Briacell, Jazz Pharmaceuticals, Inc., Atossa, Luminate; Advisor -Embiosys
Michael Khodadoust, MD	Grant or research support -Ono Pharma, Treeline Biosciences; Paid consultant -Ono Pharma
Gentry King, MD	Advisor -AstraZeneca
Ryan Lynch, MD	Grant or research support -Incyte Corporation, Genentech, Pfizer, Allogene
Sandhya Panch, MD	Honoraria -Sanofi S.A.; Speakers Bureau -Sobi
Min Park, MD, MS	Stocks or stock options, excluding diversified mutual funds -Lilly, Johnson & Johnson, Thermo Fisher Scientific
Mary-Elizabeth Percival, MD, MS	Grant or research support -Pfizer, AbbVie, Ascentage, Astex, Oncoverity
BJ Rimel, MD	Membership on Advisory Committees or Review Panels, Board Membership, etc. -GlaxoSmithKline (GSK), TEMPUS
Rachael Safyan, MD	Grant or research support -Exelixis, Verastem, Amgen, Inc., Johnson & Johnson
Rafael Santana-Davila, MD	Advisor - Amgen, Inc, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Catalyst Pharmaceuticals, Daiichi Sankyo, Inc., Genentech, Mirati Therapeutics; Grant or research support -Lilly, Beyond Spring Pharmaceuticals, Pfizer, Merck, Alx oncology, Astellas, Jounce, Alpine, Abbott
Mazyar Shadman, MD, MPH	Consulting Fee -AbbVie, AstraZeneca, BeiGene, Bristol-Myers Squibb Comp (BMS), Lilly, Fate Therapeutics, Genentech, Genmab, Janssen, Kite Pharma, Merck, MorphoSys, Nurix, Pfizer, Pierre Fabre; Grant or research support -AbbVie, AstraZeneca, BeiGene, Genentech, Genmab, Merck; Stocks or stock options, excluding diversified mutual funds -Koi Biotherapeutics
Veena Shankaran, MD	Grant or research support -Arcus Biosciences, ALX oncology, Astellas
Scott Tykodi, MD	Grant or research support -Bristol-Myers Squibb Comp (BMS), Pfizer, Exelixis, lovance Biotherapeutics, Merck, AVEO Oncology, Xencor, HiberCell

Vyshak Venur, MD	Advisor -Ono therapeutics Grant or research support -Mimivax, Fore therapeutics, Novocure
Allison Wheeler, MD	Honoraria -Pfizer, Vega Therapeutics, SeraGene, Hemab Therapeutics, Novo Nordisk, Sanofi S.A.
Kleber Yotsumoto Fertrin, MD	Advisor -Agius Pharmaceuticals
David Zhen, MD	Consulting Fee -Exelixis, Inc, Bristol-Myers Squibb Comp (BMS), Legend Biotech, Jazz Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc Grant or research support -A2 Biotherapeutics, Bristol-Myers Squibb Comp (BMS), Legend Biotech, AstraZeneca, Daiichi Sankyo, Inc, Merck, Pfizer, Lilly, Genentech, Clasp Therapeutics

The following speaker(s)/reviewer(s) have indicated they do not have any relationships to disclose:

Naveed Ali, MD	Sioban Keel, MD
Jacob Appelbaum, MD	Hiba Khan, MD
Zak Cerminara, PharmD	Mary Kwok, MD
Kara Cicero, MD	Denise McCulloch, MD
Stacey Cohen, MD	Jessica Minick, MPA (Planner, reviewer)
Alana Culberson, MBA (Planner)	Rosa Nadal Rios, MD
Meredith Fane (Planner)	Lisa Ni, MD
Shannon Fogh, MD	Lauren Shih, MD
Cristina Ghiuzeli, MD	Ritu Shriyan (Planner)
Nicholas Giustini, MD	Andrew Stergachis, MD
Lindsay Hammons, MD	Molly Tokaz, MD (Faculty, planner, reviewer)
Rida Hasan, MD	Prakash Vishnu, MD
Livia Hegerova, MD	Todd Yezefski, MD
Kristie Herbord (Planner, reviewer)	Rachel Yung, MD
Amy Indorf, PharmD	

√	Topic	Section	Credits
	Adjuvant Therapy for Breast Cancer	Breast Oncology	0.75
	Metastatic Breast Cancer	Breast Oncology	0.75
	Therapy for Non-Invasive Breast Cancer	Breast Oncology	0.75
	Anal Cancer	GI Oncology	0.25
	Cholangiocarcinoma	GI Oncology	0.5
	Colorectal Cancer	GI Oncology	1
	Esophageal/Gastric Cancer	GI Oncology	0.75
	Gastrointestinal Neuroendocrine Tumors	GI Oncology	0.5
	Hepatocellular Cancer	GI Oncology	0.75
	Pancreatic Cancer	GI Oncology	0.5
	Bladder Cancer	GU Oncology	0.75
	Prostate Cancer	GU Oncology	0.75
	Renal Cell Carcinoma	GU Oncology	0.75
	Testicular Cancer	GU Oncology	0.5
	Benign White Cell Disorders	Hematology	0.5
	Bleeding Disorders	Hematology	0.75
	Consultative Hematology	Hematology	0.5
	Hematopoietic Cell Transplantation	Hematology	0.75
	Inherited & Acquired Marrow Failure	Hematology	0.5
	Iron Metabolism Disorders & Hemolytic Anemias	Hematology	0.5
	Myelodysplastic Syndromes	Hematology	0.5
	Myeloproliferative Neoplasms	Hematology	0.5
	Thalassemia & Hemoglobinopathies	Hematology	0.75
	Thrombocytopenia	Hematology	1
	Thrombosis & Anticoagulation	Hematology	0.5
	Transfusion Medicine	Hematology	0.75
	Acute Lymphoblastic Leukemia	Leukemia and Myelomas	0.5
	Acute Myeloid Leukemia	Leukemia and Myelomas	0.75
	Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) & Hairy Cell Leukemia	Leukemia and Myelomas	0.75
	Chronic Myeloid Leukemia	Leukemia and Myelomas	0.5
	Newly Diagnosed Myeloma	Leukemia and Myelomas	0.5
	Relapsed/Refractory Myeloma & Amyloidosis	Leukemia and Myelomas	0.5
	Smoldering Myeloma & MGUS	Leukemia and Myelomas	0.25
	B-NHL, Aggressive Non-Hodgkin Lymphoma	Lymphomas	0.75
	B-NHL, Indolent Non-Hodgkin Lymphoma	Lymphomas	0.75
	Hodgkin Lymphoma	Lymphomas	0.75
	T-Cell Lymphoma - NHL	Lymphomas	0.5
	CNS Cancers	Other Malignancies	0.75
	Gynecologic Oncology - Cervical and Endometrial Cancers	Other Malignancies	0.75
	Gynecologic Oncology - Ovarian Cancer	Other Malignancies	0.5
	Melanoma and other Skin Cancers	Other Malignancies	0.75
	Sarcoma	Other Malignancies	0.75
	Familial Syndromes	Supportive Care & Associated Specialties	0.75
	Hematology Pharmacology Pearls	Supportive Care & Associated Specialties	0.75
	Infectious Disease Complications	Supportive Care & Associated Specialties	0.75
	Integrative Medicine	Supportive Care & Associated Specialties	0.5
	Radiation Oncology - Multi-Disciplinary	Supportive Care & Associated Specialties	0.5
	Solid Tumor Pharmacology Pearls	Supportive Care & Associated Specialties	0.75
	Supportive Care	Supportive Care & Associated Specialties	1
	Head, Neck and Thyroid Cancer	Thoracic, Head and Neck	0.75
	Mesothelioma	Thoracic, Head and Neck	0.25
	Non-Small Cell Lung Cancer - Adjuvant/Locally Advanced	Thoracic, Head and Neck	0.75
	Non-Small Cell Lung Cancer - Metastatic	Thoracic, Head and Neck	0.5
	Small Cell Lung Cancer	Thoracic, Head and Neck	0.5
		TOTAL (MAX 34.5)	

